{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:49:36Z","timestamp":1781538576292,"version":"3.54.5"},"publisher-location":"New York, NY","reference-count":36,"publisher":"Springer US","isbn-type":[{"value":"9781071647295","type":"print"},{"value":"9781071647301","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4730-1_4","type":"book-chapter","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:00:29Z","timestamp":1753707629000},"page":"85-93","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Milasen: The Emerging Era of Patient-Customized N-of-1 Antisense Oligonucleotides as Therapeutic Agents for Genetic Diseases"],"prefix":"10.1007","author":[{"given":"Harry","family":"Wilton-Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"issue":"5","key":"4_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1634\/theoncologist.2009-0047","volume":"14","author":"JT J\u00f8rgensen","year":"2009","unstructured":"J\u00f8rgensen JT (2009) New era of personalized medicine: a 10-year anniversary. Oncologist 14(5):557\u2013558. https:\/\/doi.org\/10.1634\/theoncologist.2009-0047","journal-title":"Oncologist"},{"issue":"2","key":"4_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2217\/pme.11.7","volume":"8","author":"EO Lillie","year":"2011","unstructured":"Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ (2011) The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med 8(2):161\u2013173","journal-title":"Per Med"},{"key":"4_CR3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-94-017-7200-6_2","volume-title":"What are N-of-1 trials? The essential guide to N-of-1 trials in health","author":"J Nikles","year":"2015","unstructured":"Nikles J (2015) What are N-of-1 trials? The essential guide to N-of-1 trials in health. Springer Netherlands, Dordrecht, pp 9\u201317"},{"issue":"4","key":"4_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamapediatrics.2020.5801","volume":"175","author":"KW Davidson","year":"2021","unstructured":"Davidson KW, Silverstein M, Cheung K, Paluch RA, Epstein LH (2021) Personalized (N-of-1) trials: a primer. JAMA Pediatr 175(4):404","journal-title":"JAMA Pediatr"},{"issue":"1","key":"4_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5582\/irdr.3.1","volume":"3","author":"AK Hall","year":"2014","unstructured":"Hall AK, Carlson MR (2014) The current status of orphan drug development in Europe and the US. Intractable Rare Dis Res 3(1):1","journal-title":"Intractable Rare Dis Res"},{"issue":"17","key":"4_CR6","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim J, Hu C, Moufawad El Achkar C, Black LE, Douville J, Larson A et al (2019) Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med 381(17):1644\u20131652","journal-title":"N Engl J Med"},{"issue":"3","key":"4_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41582-019-0138-8","volume":"15","author":"TB Johnson","year":"2019","unstructured":"Johnson TB, Cain JT, White KA, Ramirez-Montealegre D, Pearce DA, Weimer JM (2019) Therapeutic landscape for batten disease: current treatments and future prospects. Nat Rev Neurol 15(3):161","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"4_CR8","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1177\/0883073813493665","volume":"28","author":"SB Dolisca","year":"2013","unstructured":"Dolisca SB, Mehta M, Pearce DA, Mink JW, Maria BL (2013) Batten disease: clinical aspects, molecular mechanisms, translational science, and future directions. J Child Neurol 28(9):1074","journal-title":"J Child Neurol"},{"issue":"10","key":"4_CR9","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.bbadis.2006.06.010","volume":"1762","author":"M Haltia","year":"2006","unstructured":"Haltia M (2006) The neuronal ceroid-lipofuscinoses: from past to present. Biochim Biophys Acta (BBA) \u2013 Mol Basis Dis 1762(10):850\u2013856","journal-title":"Biochim Biophys Acta (BBA) \u2013 Mol Basis Dis"},{"key":"4_CR10","first-page":"73","volume":"6","author":"JR Ostergaard","year":"2016","unstructured":"Ostergaard JR (2016) Juvenile neuronal ceroid lipofuscinosis (batten disease): current insights. Degener Neurol Neuromuscul Dis 6:73","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"11","key":"4_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/21678707.2019.1684258","volume":"7","author":"JB Rosenberg","year":"2019","unstructured":"Rosenberg JB, Chen A, Kaminsky SM, Crystal RG, Sondhi D (2019) Advances in the treatment of neuronal ceroid Lipofuscinosis. Expert Opin Orphan Drugs 7(11):473","journal-title":"Expert Opin Orphan Drugs"},{"issue":"20","key":"4_CR12","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","volume":"378","author":"A Schulz","year":"2018","unstructured":"Schulz A, Ajayi T, Specchio N, de Los RE, Gissen P, Ballon D et al (2018) Study of intraventricular Cerliponase Alfa for CLN2 disease. N Engl J Med 378(20):1898\u20131907","journal-title":"N Engl J Med"},{"issue":"2","key":"4_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1699-0463.1998.tb01346.x","volume":"106","author":"A Terman","year":"1998","unstructured":"Terman A, Brunk UT (1998) Lipofuscin: mechanisms of formation and increase with age. APMIS 106(2):265\u2013276","journal-title":"APMIS"},{"issue":"4","key":"4_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1023\/A:1005564509027","volume":"22","author":"MJ Bennett","year":"1999","unstructured":"Bennett MJ, Hofmann SL (1999) The neuronal ceroid-lipofuscinoses (batten disease): a new class of lysosomal storage diseases. J Inherit Metab Dis 22(4):535\u2013544","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"4_CR15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1046\/j.1471-4159.1996.67020677.x","volume":"67","author":"SC Lane","year":"1996","unstructured":"Lane SC, Jolly RD, Schmechel DE, Alroy J, Boustany RM (1996) Apoptosis as the mechanism of neurodegeneration in batten\u2019s disease. J Neurochem 67(2):677\u2013683","journal-title":"J Neurochem"},{"issue":"2","key":"4_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/ajmg.1320570218","volume":"57","author":"SU Walkley","year":"1995","unstructured":"Walkley SU, March PA, Schroeder CE, Wurzelmann S, Jolly RD (1995) Pathogenesis of brain dysfunction in batten disease. Am J Med Genet 57(2):196\u2013203","journal-title":"Am J Med Genet"},{"issue":"1","key":"4_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-018-0300-6","volume":"14","author":"AB Mukherjee","year":"2019","unstructured":"Mukherjee AB, Appu AP, Sadhukhan T, Casey S, Mondal A, Zhang Z et al (2019) Emerging new roles of the lysosome and neuronal ceroid lipofuscinoses. Mol Neurodegener 14(1):1\u201323","journal-title":"Mol Neurodegener"},{"issue":"3","key":"4_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.devcel.2011.07.016","volume":"21","author":"DL Medina","year":"2011","unstructured":"Medina DL, Fraldi A, Bouche V, Annunziata F, Mansueto G, Spampanato C et al (2011) Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev Cell 21(3):421\u2013430","journal-title":"Dev Cell"},{"issue":"6","key":"4_CR19","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/S0002-9440(10)61253-9","volume":"167","author":"M Koike","year":"2005","unstructured":"Koike M, Shibata M, Waguri S, Yoshimura K, Tanida I, Kominami E et al (2005) Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (batten disease). Am J Pathol 167(6):1713\u20131728","journal-title":"Am J Pathol"},{"issue":"4","key":"4_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM (2017) Nusinersen: first global approval. Drugs 77(4):473\u2013479","journal-title":"Drugs"},{"key":"4_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.omtn.2023.05.025","volume":"33","author":"JL Centa","year":"2023","unstructured":"Centa JL, Stratton MP, Pratt MA, Osterlund Oltmanns JR, Wallace DG, Miller SA et al (2023) Protracted CLN3 batten disease in mice that genetically model an exon-skipping therapeutic approach. Mol Ther Nucleic Acids 33:15\u201327","journal-title":"Mol Ther Nucleic Acids"},{"issue":"9","key":"4_CR22","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/s41591-020-0986-1","volume":"26","author":"JL Centa","year":"2020","unstructured":"Centa JL, Jodelka FM, Hinrich AJ, Johnson TB, Ochaba J, Jackson M et al (2020) Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 batten disease. Nat Med 26(9):1444","journal-title":"Nat Med"},{"key":"4_CR23","doi-asserted-by":"crossref","unstructured":"Chen X, Dong T, Hu Y, Shaffo FC, Belur NR, Mazzulli JR et al (2022) AAV9\/MFSD8 gene therapy is effective in preclinical models of neuronal ceroid lipofuscinosis type 7 disease. J Clin Invest 132(5)","DOI":"10.1172\/JCI146286"},{"issue":"9","key":"4_CR24","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.febslet.2005.02.047","volume":"579","author":"N L\u00f3pez-Bigas","year":"2005","unstructured":"L\u00f3pez-Bigas N, Audit B, Ouzounis C, Parra G, Guig\u00f3 R (2005) Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett 579(9):1900\u20131903","journal-title":"FEBS Lett"},{"issue":"2","key":"4_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/humu.20400","volume":"28","author":"M Krawczak","year":"2007","unstructured":"Krawczak M, Thomas NST, Hundrieser B, Mort M, Wittig M, Hampe J et al (2007) Single base-pair substitutions in exon-intron junctions of human genes: nature, distribution, and consequences for mRNA splicing. Hum Mutat 28(2):150\u2013158","journal-title":"Hum Mutat"},{"key":"4_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.713540","volume":"12","author":"P Ren","year":"2021","unstructured":"Ren P, Lu L, Cai S, Chen J, Lin W, Han F (2021) Alternative splicing: a new cause and potential therapeutic target in autoimmune disease. Front Immunol 12:713540","journal-title":"Front Immunol"},{"key":"4_CR27","unstructured":"The Cost of Sequencing a Human Genome (2023). https:\/\/www.genome.gov\/about-genomics\/fact-sheets\/Sequencing-Human-Genome-cost"},{"key":"4_CR28","unstructured":"Children\u2019s Answers (2023) Milasen: Genetic diagnosis to custom drug, in under 1 year - Boston Children\u2019s Answers. https:\/\/answers.childrenshospital.org\/milasen-batten-disease\/"},{"issue":"7971","key":"4_CR29","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","volume":"619","author":"J Kim","year":"2023","unstructured":"Kim J, Woo S, de Gusmao CM, Zhao B, Chin DH, DiDonato RL et al (2023) A framework for individualized splice-switching oligonucleotide therapy. Nature 619(7971):828\u2013836","journal-title":"Nature"},{"issue":"4","key":"4_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.7326\/0003-4819-112-4-293","volume":"112","author":"GH Guyatt","year":"1990","unstructured":"Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, Newhouse MT (1990) The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Ann Intern Med 112(4):293\u2013299","journal-title":"Ann Intern Med"},{"issue":"8","key":"4_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/MLR.0b013e318215d90d","volume":"49","author":"NB Gabler","year":"2011","unstructured":"Gabler NB, Duan N, Vohra S, Kravitz RL (2011) N-of-1 trials in the medical literature: a systematic review. Med Care 49(8):761\u2013768","journal-title":"Med Care"},{"issue":"9","key":"4_CR32","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s11606-010-1352-7","volume":"25","author":"PA Scuffham","year":"2010","unstructured":"Scuffham PA, Nikles J, Mitchell GK, Yelland MJ, Vine N, Poulos CJ et al (2010) Using N-of-1 trials to improve patient management and save costs. J Gen Intern Med 25(9):906\u2013913","journal-title":"J Gen Intern Med"},{"key":"4_CR33","unstructured":"Wagner EH (1998) Chronic disease management special editor chronic disease management: what will it take to improve care for chronic illness? Vol. 1. Wash effective clinical practice"},{"key":"4_CR34","unstructured":"Children\u2019s Answers (2024) Custom genetic treatments: seeking a path forward \u2013 Boston children\u2019s answers. Available from: https:\/\/answers.childrenshospital.org\/custom-genetic-treatments\/"},{"key":"4_CR35","doi-asserted-by":"crossref","unstructured":"M\u00fcller AR, Brands MMMG, Van De Ven PM, Roes KCB, Cornel MC, Van Karnebeek CDM et al (2021) Systematic review of N-of-1 studies in rare genetic neurodevelopmental disorders: the power of 1. Neurology 96:529\u2013540","DOI":"10.1212\/WNL.0000000000011597"},{"issue":"17","key":"4_CR36","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1056\/NEJMe1911295","volume":"381","author":"J Woodcock","year":"2019","unstructured":"Woodcock J, Marks P (2019) Drug regulation in the era of individualized therapies. N Engl J Med 381(17):1678\u20131680","journal-title":"N Engl J Med"}],"container-title":["Methods in Molecular Biology","Exon Skipping and Inclusion Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4730-1_4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:08:59Z","timestamp":1780747739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4730-1_4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9781071647295","9781071647301"],"references-count":36,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4730-1_4","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"29 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}